Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Inc (STOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,943,110
  • Shares Outstanding, K 59,151
  • Annual Sales, $ 184,420 K
  • Annual Income, $ -6,890 K
  • EBIT $ -21 M
  • EBITDA $ -20 M
  • 60-Month Beta 1.07
  • Price/Sales 10.81
  • Price/Cash Flow N/A
  • Price/Book 5.46

Options Overview Details

View History
  • Implied Volatility 116.77% (+8.89%)
  • Historical Volatility 67.96%
  • IV Percentile 69%
  • IV Rank 59.94%
  • IV High 156.09% on 04/17/25
  • IV Low 57.95% on 05/20/25
  • Expected Move (DTE 18) 6.08 (19.13%)
  • Put/Call Vol Ratio 0.97
  • Today's Volume 61
  • Volume Avg (30-Day) 238
  • Put/Call OI Ratio 1.47
  • Today's Open Interest 4,527
  • Open Int (30-Day) 3,041
  • Expected Range 25.69 to 37.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.80
  • Number of Estimates 4
  • High Estimate -0.69
  • Low Estimate -0.89
  • Prior Year 1.90
  • Growth Rate Est. (year over year) -142.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.86 +6.39%
on 03/19/26
40.22 -21.01%
on 03/10/26
-4.64 (-12.74%)
since 02/27/26
3-Month
25.21 +26.02%
on 01/12/26
40.22 -21.01%
on 03/10/26
-0.15 (-0.47%)
since 12/26/25
52-Week
5.35 +493.83%
on 04/09/25
40.22 -21.01%
on 03/10/26
+24.56 (+340.64%)
since 03/28/25

Most Recent Stories

More News
Stoke Therapeutics Faces Mounting Losses as Earnings Loom

STOK : 31.77 (-3.29%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 31.77 (-3.29%)
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– ...

STOK : 31.77 (-3.29%)
BIIB : 187.57 (+2.03%)
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support...

STOK : 31.77 (-3.29%)
BIIB : 187.57 (+2.03%)
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine,...

STOK : 31.77 (-3.29%)
BIIB : 187.57 (+2.03%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 31.77 (-3.29%)
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

–Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA– –Changes in visual function, ocular structure and quality of life...

STOK : 31.77 (-3.29%)
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine,...

STOK : 31.77 (-3.29%)
BIIB : 187.57 (+2.03%)
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA

New Headquarters Will Support Company's Work to Deliver zorevunersen, a Potential Disease-Modifying Medicine, to Patients with Dravet Syndrome and Expansion of Research Efforts

STOK : 31.77 (-3.29%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 31.77 (-3.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford,...

See More

Key Turning Points

3rd Resistance Point 34.76
2nd Resistance Point 33.98
1st Resistance Point 32.88
Last Price 31.77
1st Support Level 31.00
2nd Support Level 30.22
3rd Support Level 29.12

See More

52-Week High 40.22
Last Price 31.77
Fibonacci 61.8% 26.90
Fibonacci 50% 22.78
Fibonacci 38.2% 18.67
52-Week Low 5.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.